TITLE

Health Economics in HIV Disease: A Review of the European Literature

AUTHOR(S)
Youle, M.; Trueman, P.; Simpson, K.
PUB. DATE
May 1999
SOURCE
PharmacoEconomics;1999 Supplement 1, Vol. 15 Issue 5, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The costs of providing healthcare resources for patients with HIV disease have continued to rise during the last 2 decades since the first outbreak of AIDS. Although new and effective therapies have become available during this time, and are increasingly being used, outcome measures for, and the economic consequences of, differing models of care are poorly documented or understood. Most available economic and clinical data, especially data documenting post-therapy outcomes, are from small, short term studies. This has led to the use of modelling to estimate which determinants can improve the quality and cost effectiveness of HIV care in the future. Although the attempt to provide what is currently perceived to be the standard of care is stretching many healthcare budgets, it is an anachronism that there are few studies of health economics in HIV disease. Most published data relate only to North America, and there remains a paucity of European studies. This paper provides a review of the available data from Europe and attempts to highlight the trends that have taken place to date.
ACCESSION #
9527018

 

Related Articles

  • Initiating HAART earlier a prudent move in HIV infections.  // PharmacoEconomics & Outcomes News;10/22/2005, Issue 389, p7 

    Presents information on a study which focused on the significance of the early initiation of highly active antiretroviral therapy among patients with HIV infections. Cost effectiveness of the strategy; Association of the strategy with quality-adjusted survival; Results of sensitivity analysis.

  • Effect of Maintaining Highly Active Antiretroviral Therapy on AIDS Events among Patients with Late-Stage HIV Infection and Inadequate Response to Therapy. Gandhi, Tejal; Wei Wei; Amin, Kamal; Kazanjian, Powel // Clinical Infectious Diseases;3/15/2006, Vol. 42 Issue 6, p878 

    Background. We evaluated the effect of maintaining highly active antiretroviral therapy (HAART) on the development of new acquired immunodeficiency syndrome (AIDS)-related events in patients with late-stage human immunodeficiency virus (HIV) infection who had suboptimal CD4+ cell count and viral...

  • Accrued HIV evidence turns treatment dogma on its head. Check, Erika // Nature;8/21/2003, Vol. 424 Issue 6951, p866 

    Focuses on the possible health risk posed by HIV drugs in patients. Inefficacy of drugs in subduing virus in HIV positive patients; Comments of various researchers on HIV therapy; Thoughts over the distribution of drugs among various developing countries.

  • A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. Hahn, K.; Arendt, G.; Braun, J. S.; von Giesen, H.-J.; Husstedt, I. W.; Maschke, M.; Straube, E.; Schielke, E. // Journal of Neurology;Oct2004, Vol. 251 Issue 10, p1260 

    Background Painful HIV-associated sensory neuropathies (HIV-SN) are a common complication of HIV infection. The pathogenesis is unknown and the treatment very limited. Gabapentin (GBP) is effective in painful diabetic neuropathy and postherpetic neuralgia and its effectiveness on painful HIV-SN...

  • The Importance of Potency and Durability in HIV Patient Antiretroviral Therapy Preferences: A Telephone Survey. Sherer Jr., Renslow D.; Fath, Michael J.; Da Silva, Barbara A.; Nicolau, Ana-Maria; Miller, Nancy L. // AIDS Patient Care & STDs;Dec2005, Vol. 19 Issue 12, p794 

    Patients who were receiving or had received antiretroviral therapy (ART) participated in 45-minute telephone interviews to evaluate the importance of major treatment attributes. A Likert scale was used to quantify and rate the importance of 9 ART attributes. Trade-off exercises allowed...

  • Universal Access to HIV Treatment versus Universal 'Test and Treat': Transmission, Drug Resistance & Treatment Costs. Wagner, Bradley G.; Blower, Sally; Cameron, D. William // PLoS ONE;Sep2012, Vol. 7 Issue 9, Special section p1 

    In South Africa (SA) universal access to treatment for HIV-infected individuals in need has yet to be achieved. Currently ∼1 million receive treatment, but an additional 1.6 million are in need. It is being debated whether to use a universal 'test and treat' (T&T) strategy to try to...

  • HIV Treatment Adherence and Sexual Functioning. Miguez-Burbano, Maria Jose; Espinoza, Luis; Lewis, John E. // AIDS & Behavior;Jan2008, Vol. 12 Issue 1, p78 

    To our knowledge, no studies have considered the bidirectional relationship between HIV infected patients’ social/sexual lives and HAART adherence. To determine it’s potential impact the study sample consisted of 135 men starting HAART and being followed for 6 months. Twenty...

  • Dispersal of HIV positive asylum seekers: national survey of UK healthcare providers. Creighton, S.; Sethi, G.; Edwards, S. G.; Miller, R. // BMJ: British Medical Journal (International Edition);8/7/2004, Vol. 329 Issue 7461, p322 

    Offers a look at a national survey of United Kingdom (UK) healthcare providers regarding the dispersal of HIV-positive asylum seekers. Statement that the UK National Asylum Support Service started a policy in 2000 of dispersing asylum seekers from London and southeast England to alternative...

  • HIV/AIDS Drugs: Funding Implications of New Combination Therapies for Federal and State Programs: HEHS-99-2.  // GAO Reports;10/14/1998, p1 

    Although state governments and private payers, such as private health insurance and charitable groups, share in the financing of medical care for people with HIV and AIDS, the federal government now picks up the tab for more than half the cost of this care. Much of the more than $5 billion in...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics